Literature DB >> 23810128

Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function.

Wayne J Morgan1, Jeffrey S Wagener, Ashley Yegin, David J Pasta, Stefanie J Millar, Michael W Konstan.   

Abstract

OBJECTIVE: To determine whether the association between high forced expiratory volume in 1 second (FEV1) and increased rate of decline in FEV1 in children with cystic fibrosis could be due to less frequent intervention after acute declines (sudden decline events) in FEV1. STUDY
DESIGN: Patients with cystic fibrosis aged 6-17 years enrolled in the Epidemiologic Study of Cystic Fibrosis were assessed for a sudden decline event, defined as a 10% relative decline in FEV1% predicted from an average of 3 consecutive stable baseline spirometries. The likelihood of therapeutic intervention within 14 days before and 56 days after this event was then related to their baseline FEV1% predicted age-specific decile using a logistic regression adjusting for age group (6-12 years, 13-17 years) and presence of Pseudomonas aeruginosa on respiratory culture.
RESULTS: A total of 10 888 patients had at least 1 sudden decline event in FEV1. Patients in the highest FEV1 decile were significantly less likely than those in the lowest decile to receive intravenous antibiotics (OR, 0.14; 95% CI, 0.11-0.18; P < .001) or be hospitalized (OR, 0.18; 95% CI, 0.14-0.23; P < .001) following decline.
CONCLUSIONS: Children and adolescents with high baseline lung function are less likely to receive a therapeutic intervention following an acute decline in FEV1, which may explain their greater rate of FEV1 decline.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Keywords:  CF; Cystic fibrosis; ESCF; Epidemiologic Study of Cystic Fibrosis; FEV(1); Forced expiratory volume in 1 second; IV; Intravenous

Mesh:

Year:  2013        PMID: 23810128      PMCID: PMC4064589          DOI: 10.1016/j.jpeds.2013.05.013

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  19 in total

1.  Defining a pulmonary exacerbation in cystic fibrosis.

Authors:  M Rosenfeld; J Emerson; J Williams-Warren; M Pepe; A Smith; A B Montgomery; B Ramsey
Journal:  J Pediatr       Date:  2001-09       Impact factor: 4.406

2.  Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

Authors:  Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson
Journal:  J Pediatr       Date:  2007-06-22       Impact factor: 4.406

3.  Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada.

Authors:  W J Morgan; S M Butler; C A Johnson; A A Colin; S C FitzSimmons; D E Geller; M W Konstan; M J Light; H R Rabin; W E Regelmann; D V Schidlow; D C Stokes; M E Wohl; H Kaplowitz; M M Wyatt; S Stryker
Journal:  Pediatr Pulmonol       Date:  1999-10

4.  Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis.

Authors:  Valerie Waters; Sanja Stanojevic; Eshetu G Atenafu; Annie Lu; Yvonne Yau; Elizabeth Tullis; Felix Ratjen
Journal:  Eur Respir J       Date:  2011-12-01       Impact factor: 16.671

5.  Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data.

Authors:  Mark D Schluchter; Michael W Konstan; Mitchell L Drumm; James R Yankaskas; Michael R Knowles
Journal:  Am J Respir Crit Care Med       Date:  2006-07-20       Impact factor: 21.405

6.  Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation.

Authors:  Don B Sanders; Rachel C L Bittner; Margaret Rosenfeld; Lucas R Hoffman; Gregory J Redding; Christopher H Goss
Journal:  Am J Respir Crit Care Med       Date:  2010-05-12       Impact factor: 21.405

7.  Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry.

Authors:  B S Zemel; A F Jawad; S FitzSimmons; V A Stallings
Journal:  J Pediatr       Date:  2000-09       Impact factor: 4.406

Review 8.  Cystic fibrosis.

Authors:  Brian P O'Sullivan; Steven D Freedman
Journal:  Lancet       Date:  2009-05-04       Impact factor: 79.321

9.  Pulmonary exacerbations in cystic fibrosis.

Authors:  Harvey R Rabin; Steven M Butler; Mary Ellen B Wohl; David E Geller; Andrew A Colin; Daniel V Schidlow; Charles A Johnson; Michael W Konstan; Warren E Regelmann
Journal:  Pediatr Pulmonol       Date:  2004-05

10.  Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients.

Authors:  Mark D Schluchter; Michael W Konstan; Pamela B Davis
Journal:  Stat Med       Date:  2002-05-15       Impact factor: 2.373

View more
  9 in total

1.  Bayesian regularization for a nonstationary Gaussian linear mixed effects model.

Authors:  Emrah Gecili; Siva Sivaganesan; Ozgur Asar; John P Clancy; Assem Ziady; Rhonda D Szczesniak
Journal:  Stat Med       Date:  2021-12-12       Impact factor: 2.373

2.  Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.

Authors:  Sonya L Heltshe; Christopher H Goss; Valeria Thompson; Scott D Sagel; Don B Sanders; Bruce C Marshall; Patrick A Flume
Journal:  Thorax       Date:  2015-04-24       Impact factor: 9.139

Review 3.  The Evolution of Cystic Fibrosis Care.

Authors:  Jessica E Pittman; Thomas W Ferkol
Journal:  Chest       Date:  2015-08       Impact factor: 9.410

4.  Risk factors for lung function decline in a large cohort of young cystic fibrosis patients.

Authors:  Jonathan Cogen; Julia Emerson; Don B Sanders; Clement Ren; Michael S Schechter; Ronald L Gibson; Wayne Morgan; Margaret Rosenfeld
Journal:  Pediatr Pulmonol       Date:  2015-06-09

Review 5.  Epidemiologic Study of Cystic Fibrosis: 25 years of observational research.

Authors:  Michael W Konstan; David J Pasta; Donald R VanDevanter; Jeffrey S Wagener; Wayne J Morgan
Journal:  Pediatr Pulmonol       Date:  2021-01-12

6.  The Presence of Exophiala dermatitidis in the Respiratory Tract of Cystic Fibrosis Patients Accelerates Lung Function Decline: A Retrospective Review of Lung Function.

Authors:  Jonathan Ayling-Smith; Lorraine Speight; Rishi Dhillon; Matthijs Backx; Philip Lewis White; Kerenza Hood; Jamie Duckers
Journal:  J Fungi (Basel)       Date:  2022-04-07

7.  Variability of FEV1 and criterion for acute pulmonary exacerbation.

Authors:  Bradlee A Jenkins; Loyd Lee Glenn
Journal:  Front Pediatr       Date:  2014-10-17       Impact factor: 3.418

8.  Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis.

Authors:  Drake C Bouzek; Clement L Ren; Misty Thompson; James E Slaven; Don B Sanders
Journal:  Pediatr Pulmonol       Date:  2022-05-03

9.  Routine spirometry in cystic fibrosis patients: impact on pulmonary exacerbation diagnosis and FEV1 decline.

Authors:  Carolina Silva Barboza de Aquino; Joaquim Carlos Rodrigues; Luiz Vicente Ribeiro Ferreira da Silva-Filho
Journal:  J Bras Pneumol       Date:  2022-06-06       Impact factor: 2.800

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.